Coronary C

Coronary CT Angiography-Derived FFR Test Can Assess Risk in Patients With Angina

In individuals with stable angina, a normal coronary CT angiography-derived fractional flow reserve (FFR) test result identified participants with a low 3-year risk of all-cause death or nonfatal spontaneous myocardial infarction (MI), including in patients with high coronary artery calcium (CAC) scores, according to a study published in Radiology "CT angiography is the first step in identifying the presence of coronary artery disease, but it doesn’t show the impact on blood flow in the arteries," said Kristian T. Madsen, MD, University Hospital of Southern Denmark, Esbjerg, Denmark. "Turbu...

Ongoing Antihypertensive Therapy Associated With Decreased Dementia Risk in Late-Life

By Denise Baez , DG News Among older adults with hypertension, use of antihypertensive medication was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life, and those on antihyp...

Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomize...

AIM An important characteristic of glucose-lowering therapies (GLTs) is their ability to prevent cardiovascular complications. We aimed to investigate the cardiorenal efficacy and general safety of GLTs. MATERIALS AND METHODS Multicentre, ra



Spotify episodes

Apple podcasts

Google podcasts

Search:
Date
Filters:
Key points
7:23

Key points from the 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Presenter: Marco Metra
Cardiology
ESC 2023
Heart Fail
2:32

Heart Failure management in the post-COVID era - Lessons from the pandemic

Presenter: Theresa McDonagh
Cardiology
ESC 2023
Highlights
9:50

Highlights of ESC2023 Congress - Heart failure in focus

Presenter: Carlos Aguiar
Cardiology
ESC 2023
Burden of
6:17

Burden of Cardiovascular Disease in the European Union

Presenter: Panos Vardas
Cardiology
ESC 2023
Prospectiv
2:40

Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19

Presenter: Mikhail Kosiborod
Cardiology
ESC 2023
When real-
8:47

When real-world data meet real patients' needs: how to optimally treat patients with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Cardiology
ESC 2023
STEP HFpEF
3:20

STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity

Presenter: Mikhail Kosiborod
Cardiology
ESC 2023
Main headl
6:52

Main headlines of 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Presenter: Theresa McDonagh
Cardiology
ESC 2023
2023 ESC G
4:36

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the cardiologist's perspective

Presenter: Nikolaus Marx
Cardiology
ESC 2023
HEART-FID:
5:40

HEART-FID: Ferric Carboxymaltose in Heart Failure with Iron Deficiency

Presenter: Robert Mentz
Cardiology
ESC 2023
DICTATE-AH
6:08

DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure

Cardiology
ESC 2023
2023 ESC G
5:28

2023 ESC Guidelines for the Management of Endocarditis

Presenter: Michael A. Borger
Cardiology
ESC 2023
OCT vs. IV
4:34

OCT vs. IVUS vs. angiography guidance: a real-time updated network meta-analysis

Presenter: Gregg Stone
Cardiology
ESC 2023
2023 ESC G
7:51

2023 ESC Guidelines for the Management of Cardiomyopathies

Presenter: Juan Pablo Kaski
Cardiology
ESC 2023
2023 ESC G
6:54

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes - from the diabetologist's perspective

Presenter: Massimo Federici
Cardiology
ESC 2023
2023 ESC G
11:14

2023 ESC Guidelines for the Management of Acute Coronary Syndromes

Presenter: Borja Ibanez
Cardiology
ESC 2023
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
Do overwei
0:54

Do overweight and obesity confer an additional risk of CAD in patients with FH?

Presenter: Amany Elshorbagy
Cardiology
Interrupti
1:17

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Presenter: Matteo Lambertini
Oncology
The Omega-
1:17

The Omega-3 Mystery: New Evidence Supports the Therapeutic Value of EPA

Presenter: Eliot A. Brinton
Cardiology
The issue
1:15

The issue of adjuvant vs neoadjuvant treatment

Presenter: Paolo A. Ascierto
Oncology
The treatm
1:19

The treatment sequence in metastatic melanoma

Presenter: Paolo A. Ascierto
Oncology
LMWH use i
1:12

LMWH use in pregnancy: The ALPINE trial

Presenter: Saskia Middeldorp
Hematology
Functional
1:19

Functional Precision Medicine in Oncology

Presenter: Anthony Letai
Oncology
The first
1:10

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Presenter: Jeffrey Weber
Oncology
Elevated L
1:18

Elevated Lipoprotein(a) as a Risk Enhancing Factor for Atherosclerotic Cardiovascular Disease

Presenter: Nathan D. Wong
Cardiology
Long-term
8:46

Long-term efficacy and safety of ixekizumab

Presenter: Andrew Blauvelt
Dermatology
Paradigm s
12:05

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Presenter: Federico Cappuzzo
Oncology
How will t
9:43

How will the current therapeutic options change the treatment of RCC in the daily practice?

Presenter: Camillo Porta
Oncology
The role o
5:58

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Presenter: David F. McDermott
Oncology
Treatment
11:50

Treatment intensification in the treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
Pembrolizu
16:35

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Presenter: Stefan N. Symeonides
Oncology
State of t
6:13

State of the art treatment of bladder cancer

Presenter: Matthew R. Zibelman
Oncology